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Objectives. The aim of the present study was to determine the association between area-level socioeconomic
disadvantage and glycaemic-related risk in health service users in the Illawarra-Shoalhaven region of New
South Wales, Australia. Methods. HbA1c values recorded between 2010 and 2012 for non-pregnant
individuals aged 18 years were extracted from the Southern.IML Research (SIMLR) database. Individuals
were assigned quintiles of the Socioeconomic Indices for Australia (SEIFA) Index of Relative Socioeconomic
Disadvantage (IRSD) according to their Statistical Area 1 of residence. Glycaemic risk categories were defined
as HbA1c 5.0-5.99% (lowest risk), 6.0-7.49% (intermediate risk) and 7.5% (highest risk). Logistic regression
models were fit with glycaemic risk category as the outcome variable and IRSD as the study variable, adjusting
for age and sex. Results. Data from 29 064 individuals were analysed. Higher disadvantage was associated with
belonging to a higher glycaemic risk category in the fully adjusted model (most disadvantaged vs least
disadvantaged quintile; odds ratio 1.74, 95% confidence interval 1.58, 1.93; P < 0.001). Conclusion. In this
geocoded clinical dataset, area-level socioeconomic disadvantage was a significant correlate of increased
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To determine the association between area-level socioeconomic disadvantage and glycaemic 
related risk in health service users in the Illawarra-Shoalhaven region of NSW, Australia. 
 
Methods  
HbA1c values recorded between 2010 and 2012 for non-pregnant individuals ≥18 years of 
age were extracted from the Southern.IML Research (SIMLR) database. Individuals were 




according to their Statistical Area 1 of residence. Glycaemic risk categories were defined as 
HbA1c 5.0-5.99% (lowest risk), 6.0-7.49% (intermediate risk) and ≥7.5% (highest risk). 
Logistic regression models were fit with glycaemic risk category as the outcome variable and 
IRSD as the study variable, adjusting for age and sex.  
 
Results  
Data from 29,064 individuals were analysed. Higher disadvantage was associated with 
belonging in a higher glycaemic risk category in the fully adjusted model (most 
disadvantaged vs. least disadvantaged quintile - OR 1.74, 95% CI 1.58, 1.93; p< 0.001).  
 
Conclusion  
In this geocoded clinical dataset, area-level socioeconomic disadvantage was a significant 
correlate of increased glycaemic related risk. Geocoded clinical data can inform more 
targeted use of health service resources, with the potential for improved health care equity 
and cost-effectiveness.  
 
What is known about the topic?  
The rapid increase in Type 2 diabetes (T2D) prevalence, both globally and nationally, is a 
major concern for the community and public health agencies. Individual socioeconomic 
disadvantage is a known risk factor for Abnormal Glucose Metabolism (AGM), including 
T2D. While small area level socioeconomic disadvantage is a known correlate of AGM in 
Australia, less is known of the association of area level disadvantage and glycaemic related 
risk in individuals with AGM.  
 




This study demonstrates a robust association between small-area level socioeconomic 
disadvantage and glycaemic related risk in regional New South Wales. The study 
demonstrates that it is feasible to use geocoded, routinely collected clinical data to identify 
communities at increased health risk.  
 
What are the implications for practitioners? 
 The identification of at-risk populations is an essential step towards targeted public health 
policy and programs aimed at reducing the burden of AGM, its complications and the 
associated economic costs. Collaboration between primary care and public health in the 
collection and use of data described in this study has the potential to enhance the 
effectiveness of both sectors.  
INTRODUCTION  
Type 2 diabetes (T2D) is a serious concern for our population, clinical services and public 
health agencies, with a marked increase in national prevalence over recent decades.1Diabetes 
is among the leading causes of morbidity and death in Australia,1 with the health impacts also 
translating into significant direct and indirect economic costs for the community.2  However, 
the disease burden associated with abnormal glucose metabolism (AGM) is not limited to 
those with glucose levels above the threshold for a formal diagnosis of T2D. Prospective 
research has demonstrated significantly increased risks of all-cause mortality with impaired 
fasting glucose and impaired glucose tolerance, and increased risk of cardiovascular-related 
mortality with impaired fasting glucose.3 In addition, the risks of developing diabetes,4 
cardiovascular disease (CVD)4–6 and all-cause mortality 4,7are increased in adults with 
elevated glycated haemoglobin (HbA1c) levels below diabetes  diagnostic thresholds. It is 
recognised that the risks for development of abnormal glucose metabolism (AGM) are 




immigrant status)8 lifestyle (e.g. smoking and exercise)9,10 and environmental (e.g. place of 
residence)11,12 factors. The importance of individual level socioeconomic status as a risk 
factor for developing T2D in high-income countries has been widely observed.13,14 
Additionally, Australian research has demonstrated that area level socioeconomic status is 
associated with the risk of developing AGM 11 and the prevalence of T2D in population-
based studies.12 
 
The geographic distribution of glycaemic related risk is of major importance to health policy. 
In those with impaired glucose tolerance, the risk of progression to T2D can be significantly 
reduced through lifestyle modification, in particular improving diet quality and increasing 
exercise levels.15,16 Tight glycaemic control in diagnosed T2D, achieved through attention to 
lifestyle management17 and medical care,18 is associated with significant secondary 
prevention of T2D complications, reducing the personal and societal costs of serious sequelae 
such as visual impairment, myocardial infarction, stroke, renal impairment and death.18 
Current international evidence demonstrates that small-area socioeconomic disadvantage is 
associated with higher risk of T2D19 and poorer measures of T2D control,20 coupled with 
variable quality in process measures of clinical T2D care.20 Identifying at a small-area level 
those communities and neighbourhoods with highest glycaemic related risk would facilitate 
targeted use of health promotion and clinical resources21 with the prospect of more cost-
effective interventions than blanket approaches might achieve. Thus, areas of socioeconomic 
deprivation represent strong candidates for health service investment to reduce the impact of 
AGM.11,22 We recently demonstrated the feasibility of using routinely collected, geocoded 
clinical data (coded to include Statistical Area identifiers of individual’s residence)  to assess 
at small area level the associations between area level disadvantage and obesity to inform 




demonstrated in the UK to identify inner-urban neighbourhoods at increased risk of T2D.21 
However, to our knowledge, there are no reports in Australia of health service wide linkage 
of glycaemic control to area level disadvantage at sufficiently small statistical area units to 
identify neighbourhoods at risk. Therefore, the primary aim of this paper was to investigate 
the relationship between small-area level socioeconomic disadvantage and glycaemia in a 
cohort of health service users by utilising routinely collected clinical data, referenced to 
glycaemia-related CVD risk, in order to identify neighbourhoods at risk to enable more 
targeted health service commissioning. The secondary aim was to assess the feasibility of 
using geocoded clinical data more broadly to inform health service commissioning.  
 
METHOD  
Study area and population  
The study area was the Illawarra-Shoalhaven region of NSW, which had an estimated 
resident population of 389,157 persons at the time of the 2011 Australian Census of 
Population and Housing.24  Data were extracted from the Southern.IML Research (SIMLR) 
Study database. This community-derived longitudinal pathology cohort is comprised of 
internally-linked and geocoded data for residents of the Illawarra-Shoalhaven Area (ISA) 
aged 18 years and over presenting for pathology testing on or after 1 January 2003. The 
SIMLR Cohort is updated and refreshed annually, and provides a near-census of private 
pathology services provided in the ISA. Socioeconomic data were obtained from the 2011 
Australian Census of Population and Housing at the Statistical Area 1 (SA1) level and 
matched to individual level data using SA1 codes present in both data sets. SA1 was the 
smallest geographic statistical unit used by Australian Bureau of Statistics for reporting 
output of the 2011 Census, with each SA1 area containing on average 400 residents with a 




Areas in the study area, exact address matching for geocoding was achieved for 95.7–97.7% 
of the SIMLR database and exact street matching for the remaining 2.3–4.3%. Geocoding 
accuracy, data integrity and record inclusion criteria are checked prior to each annual update 
being included in the SIMLR database. 
 
Study sample  
All non-pregnant persons with ≥ 1 HbA1c test between 2010 and 2012 were identified as the 
study sample. For each person in this cohort, their most recent HbA1c pathology test prior to 
31 December 2012 was extracted along with test collection date, age at test collection date 
and sex. During the study period HbA1c was only eligible for a Medicare Benefits Schedule 
(MBS) rebate for monitoring glycaemic control in diagnosed diabetes.26  However, the study 
period did coincide with the release of endorsed recommendations for the use of HbA1c for 
diagnosing diabetes in Australia.27 Thus, we anticipated that the sample was comprised of 
individuals diagnosed with diabetes according to glucose-based criteria and a proportion of 
non-Medicare rebatable HbA1c tests. We excluded cases with HbA1c < 5.0% as there is 
evidence of increased all-cause mortality associated with abnormally low HbA1c in this 
range in non-diabetic adults,4 which was beyond the scope of this study.  
 
Study and outcome variables and statistical analysis  
The study variable was the individual’s IRSD category. Geocoded data were used to assign 
Socioeconomic Indices for Australia (SEIFA) Index of Relative Socioeconomic (IRSD) 
quintiles28 to individuals based on their Statistical Area 1 (SA1) of residence at their most 
recent HbA1c test result prior to 31 December 2013. The IRSD is an aggregate measure of 
socioeconomic disadvantage derived from the 2011 Australian Census, including measures of 





The outcome variable was the individual’s glycaemic risk category according to HbA1c. 
HbA1c is a measure of glycaemia  which is not subject to the day-to-day fluctuations of 
blood sugar levels.27 Pooled analyses demonstrate a 10-20% increase in CVD risk (coronary 
heart disease and stroke) for each 1% increase in HbA1c% above a threshold of 4.6-5.0%; 
both in the general population and those with diabetes, controlling for other  classical CVD 
risk factors.6 Based on longitudinal studies,4,18 Australian guidelines,29 and to allow 
comparison with international studies,30,31 we defined glycaemic CVD  risk categories as 
HbA1c 5.0-5.9% (lowest glycaemic CVD risk), 6.0-7.4% (intermediate glycaemic CVD risk) 
and ≥7.5% (highest glycaemic CVD risk: sub-optimal diabetes control). If not previously 
diagnosed, HbA1c ≥ 6.5% is in the diagnostic range for diabetes according to Australian and 
international guidelines.32 
 
Continuous variables were described with means and standard deviations (SD) and where 
appropriate, proportions in percentages with 95% confidence intervals (CI). Within a 
generalised estimating equation (GEE) framework, we fit unadjusted and sex- and age-
adjusted ordinal logistic regression models with the 3-level glycaemic risk variable as the 
outcome and the study variable the IRSD quintile of the individual’s SA1: 1 = most 
disadvantaged, 5 = least disadvantaged. We then collapsed the lowest and intermediate risk 
categories to create a binary outcome variable of HbA1c <7.5% and ≥ 7.5%. GEE binary 
logistic models were fit for the binary outcome with IRSD quintiles as the study variable, 
adjusted for age and sex. This model allowed comparison with previous international 
research investigating area-level socioeconomic disadvantage and diabetes control that used a 
single cut-point of HbA1c <7.5% to define acceptable control.30,31 The lowest glycaemic risk 




models. All analyses were controlled for clustering of individuals within SA1 arising from 
the hierarchical data structure. Within cohort associations were expressed as odds ratios 
(ORs) and 95% CIs to provide estimates of exposure-outcome relationships applicable to the 
target population.33,34 Two-sided statistical significance was set at p<0.05. R version 3.3.1 (R 
Foundation for Statistical Computing, Vienna, Austria) was used for statistical analyses. 
 
This study was approved by the Joint University of Wollongong and Illawarra Shoalhaven 
Local Health District Human Research Ethics Committee (Health and Medical) (HE13/496). 
RESULTS  
Sample description  
We identified 29,702 SIMLR records with ≥1 HbA1c test result between 01 January 2010 
and 31 December 2012. Of these, 638 (2.1%) were excluded as their most recent HbA1c test 
result in the study period was <5.0%, resulting in a study sample of 29,064 persons. The 
median age of individuals in the sample was 67 years (IQ range 18 years) and mean age 65.2 
years (SD 14.0) with a range of 18-101 years. The gender distribution was approximately 
equal with 47.4% of the sample female. The proportion of the sample in IRSD quintile 5 
(least disadvantaged) was 14.1% (n=4085) and in IRSD 1 (most disadvantaged) 25.9% 
(n=7527). The mean HbA1c of the sample was 6.69% (SD 1.39) with median of 6.30% and 
range of 5.0-17.9%. The age groups with the highest proportion of HbA1c≥ 7.5% were 18-19 
years and 20-29 years. The proportion of the sample with HbA1c≥7.5% was higher in the 
most disadvantaged compared with the least disadvantaged IRSD quintile. Sample 
characteristics are summarised in Table 1.  
 





In both the unadjusted and adjusted ordinal logistic models, there was a significant increase 
in the odds of membership in a higher glycaemic risk category for each of IRSD quintiles 1 - 
4 in comparison with quintile 5. There was a significant increase in the odds of membership 
in a higher risk glycaemic category associated with male gender in comparison with female 
gender. There was no independent association of age with glycaemic risk category. Results of 
the unadjusted and adjusted regression models are presented in Table 2.  
 
Insert Table 2 
 
The binary logistic models demonstrated similar socioeconomic gradients with a significant 
increase in the odds of HbA1c ≥ 7.5% in each of the IRSD quintiles 1 - 4 in comparison with 
quintile 5. Male gender was associated with increased risk of HbA1c ≥ 7.5%, while 
increasing age was associated with reduced risk. Results for the binary logistic models are 
summarised in Table 3. 
 
Insert Table 3 
Alternative binary and ordinal models were tested with age as a quadratic term and with a 
term for the interaction between age and IRSD. No substantial improvement in model fit was 
found. 
DISCUSSION  
It has been previously reported in Australian research that small area-level socioeconomic 
disadvantage is associated with increased risk of developing AGM.11 This study extends 
those findings by demonstrating that small area-level disadvantage is also associated with 
higher glycaemic-related risk. We found in this sample of health service users that residents 




in the highest glycaemic risk category in comparison with health service users resident in the 
least disadvantaged neighbourhoods. Among the implications of this multiplier effect, of both 
higher incidence of AGM and higher risk glycaemia with AGM, is a high burden of 
potentially preventable CVD among the most vulnerable members of the community. Our 
finding of an association between younger age and increased glycaemic risk supports 
previous international studies from community-based cohorts.31,35 In addition, we have 
demonstrated that it is feasible to use geocoded clinical data to inform health service 
commissioning, where the goal is to improve equity in health care.  
 
Previous research in Australia has focused on the prevalence of diabetes12 or incidence of 
AGM11 in relation to area-level disadvantage, preventing direct local comparison with our 
findings. However, our analyses of routinely collected clinical data are consistent with 
research using clinical data collected in the UK, prior to the introduction in 2004 of pay for 
performance mechanisms under the Quality and Outcomes Framework (QOF).30,35 In 
particular,  pooled general practice data from a large regional cohort in the UK demonstrated 
reduced odds of HbA1c < 7.5% in persons with diabetes resident in the most disadvantaged 
quintile of neighbourhoods.30  
 
Our findings, in conjunction with previous international19 and Australian11,12 studies, have 
significant implications for the resourcing of community-level health services. We can expect 
an increased prevalence of AGM, and patients at higher risk, in the most disadvantaged 
neighbourhoods. However, there is cause for optimism that appropriately constructed 
processes of  care can make a difference for these at-risk populations36 and act as a moderator 
of the adverse associations of socioeconomic disadvantage and glycaemic related risk.37 For 




reported that cultural tailoring, use of community educators, one-to-one, individualised 
assessment and reassessment, use of treatment algorithms by nurses and doctors and high 
intensity (>10 sessions) interventions, delivered over extended periods (> six months) were 
features of interventions with increased likelihood of  positive outcomes.36 There is also 
evidence to suggest that financial incentives promoting consistency in quality diabetes care 
processes and outcomes are associated with reduced socioeconomic disparities in diabetes. 
Research from the UK following introduction of QOF, demonstrated a significant 
improvement in reported uniformity of diabetes care processes and levelling of the 
socioeconomic gradient in measures of diabetes control, including the odds of having HbA1c 
< 7.5% in residents of the most disadvantaged quintile of neighbourhoods.31  
 
Thus, there is evidence to support collaborations between state funded community health 
services, federally funded primary health networks and general practices to develop 
contextually tailored and targeted interventions to improve diabetes outcomes in 
disadvantaged neighbourhoods. However, this would require policy changes to provide 
increased, outcome contingent resources. Such policy change is supported by the recent 
Australian Diabetes Care Project, a randomised controlled trial which piloted a suite of 
quality improvement measures for primary care management of diabetes, including pay for 
performance incentives. This trial demonstrated a significant improvement in diabetes care 
process measures and HbA1c in the intervention arm, with HbA1c improvements most 
marked in those with the poorest HbA1c levels at the commencement of the trial.38 Our 
findings indicate that those with the greatest socioeconomic disadvantage are more likely to 
have the poorest glycaemic control. While assessing measures of quality of care were beyond 
the scope of this study, the relationships between area-level disadvantage, access to and 




future Australian research. Given the very high cost of diabetes-related complications,39 and 
the increased risk of these complications in disadvantaged localities as demonstrated in our 
study,  an immediate focus of research should be on the marginal health and cost benefits of 
interventions targeted to areas of greatest area-level socioeconomic disadvantage.37  
 
Limitations  
The results of this study should be interpreted in light of its limitations. The data were 
sourced from those already accessing the health system and the prevalence rates in our study 
should not be applied to the general population. The within-cohort relative risks we have 
reported are more robust.33,34 However, we were not able to discriminate between type 1 
diabetes and T2D. Additionally, we were not able to identify the proportion of non-Medicare 
rebatable HbA1c tests in the sample which were performed on patients who did not have a 
diagnosis of diabetes. Due to the nature of the data, we were not able to provide an estimate 
of the absolute CVD risk associated with HbA1c levels in our sample. Our data were also 
sourced from a single region of Australia and, as yet, not compared with other regions. 
However, given the large sample size, the diverse nature of the region from which the data 
were sourced (metropolitan and rural) and consistency with previous Australian research 
concerning prevalence of diabetes and area-level disadvantage,12 we believe our findings 
provide a credible demonstration of the area-level socioeconomic gradient in glycaemic 
related CVD risk and warrant further investigation.  
 
Conclusion  
This study has demonstrated that in regional Australian health service users, individuals from 
neighbourhoods with the highest socioeconomic disadvantage are at highest risk of poorly 




geocoded, can be used to identify neighbourhoods at higher risk from glycaemia and the 
ensuing macro- and microvascular complications. This information is particularly relevant for 
federal health funding policy and state and local government health promotion initiatives, in 
addition to increasing awareness among local healthcare providers. Such data are imperative 
for effective collaboration between the public health and primary care sectors of our health 
system. An immediate avenue of application of the data is through Primary Health Networks 
(PHNs), the Australian federally funded geographically based bodies responsible for 
coordination of primary care. By identifying discrete areas of diabetes risk with routinely 
collected data, PHNs, in collaboration with state-funded entities (e.g. Local Health Districts 
in NSW), may be able to more efficiently target health promotion and service commissioning 
for those areas most likely to benefit from intervention.21 This study supports the large 
international body of work demonstrating that providing accessible and quality health care 
services to those in the most disadvantaged communities should be a priority for health policy 
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